Application of triple exits linker for temperature regulation of ovarian cancer patients with ascites during hyperthermic peritoneal perfusion
10.3781/j.issn.1000-7431.2016.44.715
- Author:
Baona WANG
1
Author Information
1. Department of Oncology, Second Affiliated Hospital of xi'An Jiaotong University
- Publication Type:Journal Article
- Keywords:
Antineoplatic combined chemotherapy protocols;
Malignant ascites;
Ovarian neoplasms;
Peritoneal lavage
- From:
Tumor
2016;36(1):90-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the efficacy of triple exits linker for temperature regulation of ovarian cancer patients with ascites in hyperthermic intraperitoneal perfusion using HGGZ-102 type body cavity heat perfusion machine. Methods: From April 2013 to September 2014, 39 ovarian cancer patients with ascites did not use triple exits linker (as the control group). From October 2014 to May 2015, 45 ovarian cancer patients with ascites used triple exits linker during hyperthermic intraperitoneal perfusion (as the study group). The patients in two groups were treated with TP regimen (paclitaxel on d 1, and hyperthermic peritoneal perfusion with cisplatin on d 1 and d 8; repeated every 3 weeks with a total of six cycles). The temperature of the drugs inflowing into abdominal cavity and outflowing from abdominal cavity in two groups was examined. Results: In the study group, the threshold temperatures of the drugs inflowing into abdominal cavity for three cycles were precisely controlled at 43.5-44.5 , and the maximal temperature when drugs outflowing from abdominal cavity reached target temperature (39.5-40.5 ). The effective rates of ascite subsided were 71.1% and 46.2% in the study group and the control group, respectively. There was significant difference between the two groups (P < 0.05). The incidence rate of adverse reaction between the two groups had no statistically significant difference (P > 0.05). Conclusion: Application of triple exits linker for temperature regulation of ovarian cancer patients with ascites in hyperthermic intraperitoneal perfusion can control the temperature accurately and improve the therapeutic effect.
